Key result
Long-term anticoagulation in DCM lacks controlled trial data, prompting recommendations for a national registry.
Why the study?
Does long-term anticoagulation reduce thromboembolic events in patients with dilated cardiomyopathy?
Does long-term anticoagulation reduce thromboembolic events in patients with dilated cardiomyopathy?
Highlights the lack of controlled data on anticoagulation in dilated cardiomyopathy and proposes a national registry to evaluate risks and benefits.
No takes yet. Share an insight, caveat, or question.
Anticoagulation decisions in dilated cardiomyopathy should remain individualized; leaves open the value of a national registry to quantify thromboembolic and bleeding risks.
Koniaris et al. (1998) conducted a review in Dilated cardiomyopathy. Long-term anticoagulation vs. No anticoagulation was evaluated on Thromboembolic events and bleeding complications. Long-term anticoagulation in patients with dilated cardiomyopathy lacks controlled trial data, prompting a recommendation for a national registry to evaluate thromboembolic and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: